Romozzi M, Iannone LF, Russo A, Finkelstein I, Seabi D, Ahlden A, Aamodt AH, Vollono C, Calabresi P, Caronna E, Pozo-Rosich P, Tronvik EA, Sundal C (2026)
Triple Preventive Therapy with OnabotulinumtoxinA, Fremanezumab, and Atogepant in Treatment-Resistant Chronic Migraine: A 52-Week Pilot Case Series (TRIPLE Cohort)
Neurol Ther (in press)
DOI 10.1007/s40120-026-01045-4, PubMed 42839214

Helland GB, Enriquez B, Beyer MK, Rise HS, Ihle-Hansen H, Andersson S, Grambaite R, Stangeland H, Vaskinn A, Ihle-Hansen H, Harbo HF, Høgestøl EA, Hagberg G, Aamodt AH (2026)
Response to "letter to the editor" by Zhang and Liu, concerning "long-term social cognitive impairment after ischemic stroke: Frequency and association with lesion volume and location in an exploratory pilot study"
J Neurol Sci, 490, 126138
DOI 10.1016/j.jns.2026.126138, PubMed 42636687

Helland GB, Enriquez B, Beyer MK, Rise HS, Ihle-Hansen H, Andersson S, Grambaite R, Stangeland H, Vaskinn A, Ihle-Hansen H, Harbo HF, Høgestøl EA, Hagberg G, Aamodt AH (2026)
Long-term social cognitive impairment after ischemic stroke: Frequency and association with lesion volume and location in an exploratory pilot study
J Neurol Sci, 489, 126075
DOI 10.1016/j.jns.2026.126075, PubMed 42391747